Spectrum Science, a 2024 MM+M Agency 100 honoree, hired Jill Beene as president of advertising and consulting, Lauren Ankeles as EVP of operations and transformation, as well as Natalie Newman as ...

Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved ...

Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...

Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue ...

(RTTNews) - Invivyd, Inc. (IVVD) announced Loss for full year that decreased from the same period last year but missed the Street estimates. The company's bottom line totaled -$169.93 million ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...